Familial Myeloproliferative Disorders
| Status: | Recruiting |
|---|---|
| Conditions: | Cancer, Hematology |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | 7 - Any |
| Updated: | 7/28/2016 |
| Start Date: | March 2008 |
| End Date: | June 2017 |
| Contact: | Josef Prachal, MD |
| Email: | Josef.prchal@hsc.utah.edu |
| Phone: | (801) 585-3229 |
Molecular Biology of Familial Myeloproliferative Disorders
Myeloproliferative disorders occur in families, thus giving rise to the theory that it is a
genetic disease that may be caused by an abnormal gene in the DNA that can be passed from
one generation of family members to another. DNA can be gathered from family members through
blood samples and the investigators will investigate (through DNA testing) to see if there
are abnormal genes that may be responsible for causing the MPDs. Understanding which genes
are responsible for causing MPDs can help develop ways to identify people who may be at risk
for developing an MPD, allow for the development of better treatments, possibly a cure, or
even prevent the development of MPDs.
genetic disease that may be caused by an abnormal gene in the DNA that can be passed from
one generation of family members to another. DNA can be gathered from family members through
blood samples and the investigators will investigate (through DNA testing) to see if there
are abnormal genes that may be responsible for causing the MPDs. Understanding which genes
are responsible for causing MPDs can help develop ways to identify people who may be at risk
for developing an MPD, allow for the development of better treatments, possibly a cure, or
even prevent the development of MPDs.
Inclusion Criteria:
- Families with 2 or more members diagnosed with polycythemia vera (PV), essential
thrombocythemia (ET), PV and ET related myelofibrosis (PV-MF and ET-MF), idiopathic
myelofibrosis (IM) or chronic myelogenous leukemia (CML).
- Healthy family members of subjects diagnosed with a myeloproliferative neoplasm
(MPN).
- Participating subjects must be 7 years of age or older
- A written assent, parental permission or consent must be obtained prior to any study
procedures being performed.
Exclusion Criteria:
- Subjects who have a known acquired cause of polycythemia (increased
hemoglobin/hematocrit), such as people living in high altitudes (in excess of 14,000
feet), subjects with heart disease, left to right heart shunt, severe hypoxia,
cyanotic congenital heart disease, or severe pulmonary disease, will be excluded from
this study, secondary forms of thrombocytosis and secondary forms of myelofibrosis.
We found this trial at
6
sites
2035 W Taylor St
Chicago, Illinois
Chicago, Illinois
(312) 996-4350
Principal Investigator: Damiano Rondelli, MD
University of Illinois at Chicago A major research university in the heart of one of...
Click here to add this to my saved trials
201 Presidents Circle
Salt Lake City, Utah 84108
Salt Lake City, Utah 84108
801) 581-7200
Principal Investigator: Josef Prachal, MD
University of Utah Research is a major component in the life of the U benefiting...
Click here to add this to my saved trials
Click here to add this to my saved trials
New York, New York 10065
Principal Investigator: Richard Silver, MD
Phone: 877-267-6355
Click here to add this to my saved trials
Click here to add this to my saved trials
3700 O St NW
Washington, District of Columbia 20057
Washington, District of Columbia 20057
(202) 687-0100
Principal Investigator: Craig Kessler, MD
Georgetown University Georgetown University is one of the world's leading academic and research institutions, offering...
Click here to add this to my saved trials